Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Ensaio Clínico da Solução Nebulizadora de Molgramostim Inalado na Proteinose Alveolar Pulmonar Autoimune (aPAP) (IMPALA-2)

2 de novembro de 2026 atualizado por: Savara Inc.

Um ensaio clínico randomizado, duplo-cego e controlado por placebo de solução de nebulização de molgramostim inalado uma vez ao dia em indivíduos adultos com proteinose alveolar pulmonar autoimune (aPAP)

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This is an interventional, randomized, double-blind, 2-arm, parallel groups, placebo-controlled, multi-center, phase 3 trial in adult subjects who are diagnosed with aPAP.

An aPAP diagnosis should be confirmed by a Granulocyte-macrophage colony stimulating factor (GM-CSF) auto-antibody test result, and history of PAP based on either high resolution computed tomography, lung biopsy, or bronchoalveolar lavage cytology, should be available.

The trial consists of a 6-week screening period, a 48-week randomized, double-blind treatment period, a 96-week open-label treatment period, and a conditional 4-week safety follow-up period. The maximum treatment duration will be 145 weeks and the maximum trial duration will be 156 weeks. During the trial, whole lung lavage will be allowed as rescue treatment in case of worsening of aPAP.

Tipo de estudo

Intervencional

Inscrição (Real)

164

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Alemanha, 69126
        • Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg
    • Bavaria
      • Muenchen-Gauting, Bavaria, Alemanha, 82131
        • Asklepios Fachkliniken Muenchen-Gauting
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Alemanha, 45239
        • Ruhrlandklinik Westdeutsches Lungenzentrum
    • New South Wales
      • Camperdown, New South Wales, Austrália, 2050
        • Royal Prince Alfred Hospital
      • Westmead, New South Wales, Austrália, 2145
        • Westmead Hospital
    • Brussels Capital
      • Brussels, Brussels Capital, Bélgica, 1070
        • Hôpital Erasme
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Bélgica, 3000
        • UZ Leuven - Campus Gasthuisberg - Pneumologie
    • Alberta
      • Calgary, Alberta, Canadá, T2N 4N1
        • University of Calgary
    • Ontario
      • Hamilton, Ontario, Canadá, L8N 4A6
        • St Joseph's Healthcare Hamilton Research
    • Quebec
      • Québec, Quebec, Canadá, G1V 4G5
        • University Institute of Cardiology and Respirology of Quebec
      • Seoul, Coréia do Sul, 03080
        • Seoul National University Hospital
      • Seoul, Coréia do Sul, 05505
        • Asan Medical Center
      • Seoul, Coréia do Sul, 06351
        • Samsung Medical Center
      • Seoul, Coréia do Sul, 03722
        • Severance Hospital - Yonsei University Health System - Pulmonary
    • Catalonia
      • Barcelona, Catalonia, Espanha, 08907
        • Hospital Universitario de Bellvitge
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • University Of Arkansas For Medical Services
    • California
      • Los Angeles, California, Estados Unidos, 90095
        • UCLA David Geffen School of Medicine
    • Colorado
      • Denver, Colorado, Estados Unidos, 80206
        • National Jewish Health
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520
        • Yale University
    • Florida
      • Gainesville, Florida, Estados Unidos, 32610
        • University of Florida Health
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University
    • Illinois
      • Maywood, Illinois, Estados Unidos, 60153
        • Loyola University
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University in St. Louis
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University Medical Center
      • Raleigh, North Carolina, Estados Unidos, 27610
        • Wake Med Health & Hospital
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229-3039
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania Perelman School of Medicine - Pulmonology
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • University of Pittsburgh
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • UT Southwestern Medical Center
    • Auvergne-Rhône-Alpes
      • Bron, Auvergne-Rhône-Alpes, França, 69500
        • Hôpital Louis Pradel
    • Brittany Region
      • Rennes, Brittany Region, França, 35033
        • CHU Pontchaillou
      • Athens, Grécia, 12462
        • Attikon University Hospital
    • Utrecht
      • Nieuwegein, Utrecht, Holanda, 3435CM
        • St Antonius Hospital
      • Dublin, Irlanda, DO4 T6F4
        • St. Vincent's University Hospital
    • Lombardy
      • Pavia, Lombardy, Itália, 27100
        • Fondazione IRCCS Policlinico San Matteo
      • Nagakute, Japão, 480-1195
        • Aichi Medical University Hospital
    • Chiba
      • Chiba, Chiba, Japão, 260-8677
        • Chiba University Hospital - Respiratory Medicine
    • Hokkaidô
      • Sapporo, Hokkaidô, Japão, 060-8648
        • Hokkaido University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japão, 236-0051
        • Kanagawa Cardiovascular and Respiratory Center
    • Kumamoto
      • Kumamoto, Kumamoto, Japão, 860-8556
        • Kumamoto University Hospital
    • Miyagi
      • Sendai, Miyagi, Japão, 980-8574
        • Tohoku University Hospital - Respiratory Tract Medicine
    • Osaka
      • Sakai, Osaka, Japão, 591-8555
        • National Hospital Organization Kinki-Chuo Chest medical Center
    • Saitama
      • Saitama, Saitama, Japão, 330-8553
        • Saitama Red Cross Hospital
    • Tokyo
      • Mitaka, Tokyo, Japão, 181-8611
        • Kyorin University Hospital
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polônia, 01-138
        • Instytut Gruzlicy i Chorob Pluc
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1769-001
        • Hospital Pulido Valente
    • Porto District
      • Porto, Porto District, Portugal, 4200-319
        • Hospital São João
    • London
      • London, London, Reino Unido, SW3 6NP
        • Royal Brompton and Harefield NHS Foundation Trust
    • Bucharest
      • Bucharest, Bucharest, Romênia, 050159
        • Institutul de Pneumoftiziologie "Marius Nasta"
    • Ankara
      • Ankara, Ankara, Turquia (Türkiye), 6010
        • Health Sciences University Gulhane Training and Research Hospital
    • Istanbul
      • Istanbul, Istanbul, Turquia (Türkiye), 34020
        • Yedikule Chest Disease and Surgery Training and Research Hospital
    • İzmir
      • Bornova, İzmir, Turquia (Türkiye), 35100
        • Ege University Hospital - Department of Pulmonology

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Subject must be ≥18 years of age, at the time of signing the informed consent (≥20 in Japan).

  2. A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.

  3. History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.

  4. A diffusing capacity for carbon monoxide of 70% predicted or lower adjusted for hemoglobin (%DLCOadj) at the screening and baseline visits.

  5. Change in %DLCO adj of <15% points during the screening period.

  6. Demonstrated functional impairment in the treadmill exercise test (defined as a peak metabolic equivalent (MET) ≤8).

  7. Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.

  8. Resting oxygen saturation (SpO2) >85% during 15 minutes without use of supplemental oxygen at the screening visits.

  9. Male or female

  10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate contraception as described below.
    2. Female subjects: Females who have been post-menopausal for >1 year, or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence*), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at the screening visits, and a negative urine pregnancy test at Baseline visit (Visit 3) and must not be lactating.
  11. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.

Exclusion Criteria:

  1. Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
  2. Whole lung lavage (WLL) performed within 3 months prior to baseline.
  3. Requirement for WLL at screening or baseline.
  4. GM-CSF treatment within 6 months prior to baseline.
  5. Treatment with rituximab within 6 months prior to baseline.
  6. Treatment with plasmapheresis within 6 weeks prior to baseline.
  7. Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
  8. Previously randomized in this trial.
  9. History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
  10. Inflammatory or autoimmune disease of a severity that necessitates significant (e.g. more than 10 mg/day systemic prednisolone) immunosuppression.
  11. Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
  12. History of, or present, myeloproliferative disease or leukemia.
  13. Apparent pre-existing concurrent pulmonary fibrosis.
  14. Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.
  15. Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial.
  16. Physical disability or other condition that precludes safe and adequate exercise testing.
  17. Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
  18. Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For France only: including as further defined by French Health Code L-1121-5.
  19. For France only: Any subject considered to be "vulnerable" on account of, e.g., mental or physical disability, socio-economic situation, or subjects deprived of their liberty. For France only: including as further defined by French Health Code L1121-8-1.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Molgramostim

Double-blind treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 48 weeks

Molgramostim 300 µg nebulizer solution

Outros nomes:
  • Fator estimulante de colônia de granulócitos-macrófagos humanos recombinantes (rhGM-CSF)
Comparador de Placebo: Placebo

Double-blind treatment with placebo (PBO) nebulizer solution once daily for 48 weeks

Matching placebo nebulizer solution

Outros nomes:
  • Nebulizador de placebo
Experimental: Molgramostim Open-label Extension

Open-label treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 96 weeks

Molgramostim 300 µg nebulizer solution

Outros nomes:
  • Fator estimulante de colônia de granulócitos-macrófagos humanos recombinantes (rhGM-CSF)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
Prazo: From Baseline to Week 24

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj).

From Baseline to Week 24

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48
Prazo: From Baseline to Week 48

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). Higher values indicate better respiratory gas exchange.

From Baseline to Week 48
Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24
Prazo: From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 24
Change From Baseline in SGRQ Activity Component Score to Week 24
Prazo: From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 24
Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24
Prazo: From Baseline to Week 24

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 24
Change From Baseline in SGRQ Total Score to Week 48
Prazo: From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 48
Change From Baseline in SGRQ Activity From Baseline to Week 48
Prazo: From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 48
Change From Baseline in EC, Expressed as Peak METs to Week 48
Prazo: From Baseline to Week 48

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 48
Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects)
Prazo: From Baseline to Week 24

A-aDO2 was used as an additional measure of gas exchange.

From Baseline to Week 24
Number of Subjects With Serious and Non-serious Adverse Events
Prazo: From Baseline until End of Double-blind treatment (Week 48)

Assessment of the safety of molgramostim compared to placebo

From Baseline until End of Double-blind treatment (Week 48)
Number of Subjects With Positive Treatment-boosted Anti Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Antibody Titers During 24 Weeks' Treatment and During 48 Weeks' Treatment
Prazo: From Baseline until End of Double-blind treatment Week-48

Assess the effect of molgramostim or placebo on antiGM-CSF antibody titers that increased by a dilution factor of 2.(4X increase in titer compared to Baseline).

From Baseline until End of Double-blind treatment Week-48
Changes in Forced Vital Capacity (FVC) %Predicted Normal
Prazo: From Baseline to Weeks 24 and 48

Forced vital capacity is the volume of air that can be expired after a deep breath. Higher volumes indicate better respiratory function. FVC is scored as % of predicted normal expired vital capacity.

From Baseline to Weeks 24 and 48
Changes in Forced Expiratory Volume in One Second (FEV1) % Predicted Normal.
Prazo: From Baseline to Weeks 24 and 48

FEV1 is the volume of air expired in 1 second in liters (L). Higher values indicate better respiratory function.

From Baseline to Weeks 24 and 48
Change in QT Interval Corrected by Fridericia (QTcF)
Prazo: From Baseline to Weeks 4 and 24

Assessment of the safety of MOL compared to placebo

From Baseline to Weeks 4 and 24

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Bruce Trapnell, MD, Children's Hospital Medical Center, Cincinnati

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

19 de maio de 2021

Conclusão Primária (Real)

30 de novembro de 2023

Conclusão do estudo (Estimado)

30 de maio de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

3 de setembro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de setembro de 2020

Primeira postagem (Real)

10 de setembro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • SAV006-05
  • 2020-001263-85 (Número EudraCT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .